| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries | 28 | 2014 | 768 | 1.820 |
Why?
|
| Microdialysis | 19 | 2011 | 57 | 1.500 |
Why?
|
| Nervous System Diseases | 3 | 2018 | 375 | 0.840 |
Why?
|
| Cerebral Cortex | 14 | 2011 | 452 | 0.810 |
Why?
|
| Brain Neoplasms | 16 | 2019 | 1216 | 0.780 |
Why?
|
| Craniocerebral Trauma | 11 | 2002 | 139 | 0.720 |
Why?
|
| Spinal Cord | 12 | 2004 | 302 | 0.680 |
Why?
|
| Glycine | 7 | 1997 | 168 | 0.620 |
Why?
|
| Cerebrovascular Circulation | 10 | 2011 | 463 | 0.580 |
Why?
|
| Problem Behavior | 1 | 2018 | 37 | 0.560 |
Why?
|
| Glioma | 5 | 2022 | 492 | 0.560 |
Why?
|
| Spinal Cord Injuries | 6 | 1996 | 313 | 0.540 |
Why?
|
| Meningeal Neoplasms | 6 | 2019 | 185 | 0.520 |
Why?
|
| Brain | 16 | 2019 | 2999 | 0.490 |
Why?
|
| Alcoholism | 1 | 2018 | 231 | 0.490 |
Why?
|
| Meningioma | 7 | 2019 | 120 | 0.470 |
Why?
|
| Amino Acids | 9 | 1996 | 668 | 0.470 |
Why?
|
| Bariatric Surgery | 1 | 2015 | 119 | 0.440 |
Why?
|
| Extracellular Space | 7 | 2010 | 87 | 0.430 |
Why?
|
| Lactic Acid | 6 | 2004 | 153 | 0.430 |
Why?
|
| Neurotransmitter Agents | 6 | 1996 | 147 | 0.420 |
Why?
|
| Thymidine Kinase | 7 | 2000 | 95 | 0.360 |
Why?
|
| Monitoring, Physiologic | 6 | 2011 | 377 | 0.360 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2011 | 219 | 0.350 |
Why?
|
| Motor Cortex | 5 | 1996 | 77 | 0.330 |
Why?
|
| Biomarkers | 5 | 2016 | 3090 | 0.300 |
Why?
|
| Ischemia | 7 | 1994 | 362 | 0.290 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2008 | 76 | 0.290 |
Why?
|
| Brain Ischemia | 7 | 2004 | 265 | 0.280 |
Why?
|
| Prolactin | 1 | 2008 | 114 | 0.280 |
Why?
|
| Growth Hormone | 1 | 2008 | 150 | 0.280 |
Why?
|
| Rabbits | 14 | 1996 | 718 | 0.280 |
Why?
|
| Nitric Oxide | 7 | 2011 | 493 | 0.280 |
Why?
|
| Rats | 23 | 2019 | 3716 | 0.260 |
Why?
|
| Nitrates | 4 | 2003 | 29 | 0.260 |
Why?
|
| Neuralgia | 2 | 1997 | 44 | 0.260 |
Why?
|
| Nitrites | 4 | 2003 | 49 | 0.260 |
Why?
|
| Spinal Cord Neoplasms | 3 | 2014 | 72 | 0.260 |
Why?
|
| Erythropoietin | 3 | 2014 | 105 | 0.260 |
Why?
|
| Intensive Care Units | 1 | 2009 | 493 | 0.240 |
Why?
|
| Animals | 50 | 2019 | 34219 | 0.240 |
Why?
|
| Gene Transfer Techniques | 2 | 1997 | 354 | 0.230 |
Why?
|
| Gliosarcoma | 2 | 2004 | 10 | 0.230 |
Why?
|
| Neuroprotective Agents | 4 | 2011 | 163 | 0.230 |
Why?
|
| Simplexvirus | 6 | 2000 | 104 | 0.230 |
Why?
|
| Humans | 70 | 2022 | 125167 | 0.230 |
Why?
|
| Glutamic Acid | 6 | 2010 | 203 | 0.230 |
Why?
|
| Adult | 40 | 2022 | 29634 | 0.220 |
Why?
|
| Frontal Lobe | 2 | 2005 | 116 | 0.220 |
Why?
|
| Nerve Sheath Neoplasms | 2 | 2014 | 23 | 0.220 |
Why?
|
| Ganciclovir | 6 | 2000 | 103 | 0.220 |
Why?
|
| Ischemic Attack, Transient | 4 | 1999 | 57 | 0.220 |
Why?
|
| Postoperative Complications | 1 | 2015 | 3071 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 1142 | 0.210 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2019 | 379 | 0.200 |
Why?
|
| Glucose | 6 | 2004 | 877 | 0.200 |
Why?
|
| Cytokines | 2 | 2008 | 1288 | 0.200 |
Why?
|
| Middle Aged | 31 | 2019 | 26932 | 0.200 |
Why?
|
| Seizures | 3 | 2019 | 872 | 0.200 |
Why?
|
| Ophthalmoplegia | 2 | 2000 | 54 | 0.190 |
Why?
|
| Granuloma | 2 | 2012 | 68 | 0.190 |
Why?
|
| Male | 54 | 2022 | 61503 | 0.190 |
Why?
|
| Female | 49 | 2022 | 66783 | 0.190 |
Why?
|
| Dialysis | 6 | 1993 | 22 | 0.190 |
Why?
|
| Avian Sarcoma Viruses | 4 | 2000 | 32 | 0.190 |
Why?
|
| HIV Infections | 3 | 2022 | 1897 | 0.190 |
Why?
|
| Brain Diseases | 2 | 2012 | 300 | 0.190 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1694 | 0.190 |
Why?
|
| Hypoxia, Brain | 3 | 1998 | 34 | 0.190 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 64 | 0.190 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2014 | 235 | 0.180 |
Why?
|
| Evoked Potentials | 7 | 1996 | 145 | 0.170 |
Why?
|
| Muscle Spasticity | 3 | 1996 | 73 | 0.170 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2000 | 17 | 0.170 |
Why?
|
| Inflammation | 1 | 2008 | 1447 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 3157 | 0.170 |
Why?
|
| Glycine Agents | 2 | 1997 | 10 | 0.170 |
Why?
|
| Cavernous Sinus | 1 | 2000 | 22 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2000 | 33 | 0.170 |
Why?
|
| Neurilemmoma | 2 | 2014 | 44 | 0.170 |
Why?
|
| H-Reflex | 2 | 1996 | 13 | 0.170 |
Why?
|
| Glioblastoma | 2 | 2022 | 330 | 0.160 |
Why?
|
| Neurocysticercosis | 2 | 2012 | 27 | 0.160 |
Why?
|
| Kv Channel-Interacting Proteins | 1 | 2019 | 32 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2019 | 3572 | 0.160 |
Why?
|
| Blepharoptosis | 1 | 2000 | 67 | 0.160 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 1997 | 94 | 0.160 |
Why?
|
| Sciatic Nerve | 2 | 1996 | 55 | 0.160 |
Why?
|
| Somatosensory Cortex | 1 | 2019 | 53 | 0.150 |
Why?
|
| Iatrogenic Disease | 1 | 1999 | 133 | 0.150 |
Why?
|
| Genetic Vectors | 6 | 2000 | 936 | 0.150 |
Why?
|
| Dura Mater | 1 | 1998 | 25 | 0.150 |
Why?
|
| Neurosurgery | 1 | 1999 | 74 | 0.150 |
Why?
|
| Hemangioma, Cavernous | 1 | 1998 | 19 | 0.150 |
Why?
|
| Oxygen | 8 | 2010 | 556 | 0.150 |
Why?
|
| Hemianopsia | 1 | 1998 | 22 | 0.150 |
Why?
|
| Carbon | 1 | 2019 | 92 | 0.150 |
Why?
|
| Magnesium | 1 | 1999 | 123 | 0.150 |
Why?
|
| Encephalitis | 1 | 2019 | 111 | 0.150 |
Why?
|
| Foreign Bodies | 1 | 1999 | 104 | 0.150 |
Why?
|
| Vision Disorders | 1 | 2000 | 211 | 0.150 |
Why?
|
| Coma | 2 | 1996 | 56 | 0.150 |
Why?
|
| Excitatory Amino Acids | 2 | 1998 | 9 | 0.140 |
Why?
|
| Potassium | 1 | 1999 | 282 | 0.140 |
Why?
|
| Erdheim-Chester Disease | 1 | 2017 | 25 | 0.140 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 228 | 0.140 |
Why?
|
| Brain Chemistry | 2 | 2000 | 125 | 0.140 |
Why?
|
| Defective Viruses | 1 | 1997 | 18 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 397 | 0.140 |
Why?
|
| Hyperalgesia | 1 | 1997 | 25 | 0.140 |
Why?
|
| Mechanoreceptors | 1 | 1996 | 11 | 0.130 |
Why?
|
| Nociceptors | 1 | 1996 | 15 | 0.130 |
Why?
|
| Analgesia, Epidural | 1 | 1997 | 29 | 0.130 |
Why?
|
| Pentobarbital | 1 | 1996 | 20 | 0.130 |
Why?
|
| Diagnosis, Differential | 7 | 2014 | 1896 | 0.130 |
Why?
|
| Nanoparticles | 1 | 2019 | 232 | 0.130 |
Why?
|
| Antimetabolites | 1 | 1996 | 33 | 0.130 |
Why?
|
| Paraganglioma | 1 | 1996 | 20 | 0.130 |
Why?
|
| Antioxidants | 1 | 2019 | 369 | 0.130 |
Why?
|
| Adenoviruses, Human | 1 | 1996 | 81 | 0.130 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 237 | 0.130 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2004 | 149 | 0.120 |
Why?
|
| Pituitary Neoplasms | 2 | 2007 | 80 | 0.120 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2015 | 10 | 0.120 |
Why?
|
| Perioperative Period | 1 | 2015 | 51 | 0.120 |
Why?
|
| Hypnotics and Sedatives | 1 | 1996 | 132 | 0.120 |
Why?
|
| Rats, Long-Evans | 7 | 2019 | 102 | 0.120 |
Why?
|
| Disease Progression | 2 | 2019 | 2064 | 0.120 |
Why?
|
| Viral Proteins | 1 | 1997 | 347 | 0.120 |
Why?
|
| Arginine | 5 | 2011 | 334 | 0.120 |
Why?
|
| Blindness | 1 | 2015 | 71 | 0.120 |
Why?
|
| Repressor Proteins | 1 | 2019 | 813 | 0.120 |
Why?
|
| Hippocampus | 6 | 2010 | 824 | 0.110 |
Why?
|
| Meningoencephalitis | 1 | 2014 | 18 | 0.110 |
Why?
|
| Genetic Therapy | 5 | 2011 | 687 | 0.110 |
Why?
|
| Disease Models, Animal | 7 | 2012 | 4392 | 0.110 |
Why?
|
| Calcium | 1 | 1999 | 1102 | 0.110 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 1993 | 43 | 0.110 |
Why?
|
| Frontal Sinus | 1 | 2013 | 11 | 0.110 |
Why?
|
| Nutritional Status | 1 | 2015 | 314 | 0.110 |
Why?
|
| Lipoma | 2 | 1994 | 24 | 0.110 |
Why?
|
| Breast Neoplasms | 3 | 2013 | 2512 | 0.110 |
Why?
|
| Xanthomatosis | 1 | 1993 | 7 | 0.110 |
Why?
|
| Choroid Plexus | 1 | 1993 | 23 | 0.100 |
Why?
|
| Erythrocyte Transfusion | 1 | 2014 | 130 | 0.100 |
Why?
|
| Glasgow Coma Scale | 4 | 2008 | 206 | 0.100 |
Why?
|
| Encephalocele | 1 | 2013 | 51 | 0.100 |
Why?
|
| Intracranial Pressure | 5 | 2010 | 197 | 0.100 |
Why?
|
| Hemoglobins | 1 | 2014 | 311 | 0.100 |
Why?
|
| SEER Program | 1 | 2014 | 202 | 0.100 |
Why?
|
| Cerebral Ventricles | 1 | 1993 | 81 | 0.100 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2008 | 105 | 0.100 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2013 | 74 | 0.100 |
Why?
|
| Jugular Veins | 3 | 1998 | 77 | 0.100 |
Why?
|
| Substance P | 1 | 2012 | 36 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 1998 | 345 | 0.100 |
Why?
|
| Sarcoma | 1 | 2014 | 182 | 0.090 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2022 | 24 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2012 | 1241 | 0.090 |
Why?
|
| Aged | 13 | 2019 | 19871 | 0.090 |
Why?
|
| Glucuronidase | 1 | 2011 | 32 | 0.090 |
Why?
|
| Immunohistochemistry | 5 | 2007 | 1695 | 0.090 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2011 | 18 | 0.090 |
Why?
|
| Toxoplasmosis | 1 | 2011 | 21 | 0.090 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2010 | 29 | 0.090 |
Why?
|
| Cerebrum | 1 | 2010 | 33 | 0.090 |
Why?
|
| Antigens, CD34 | 2 | 2008 | 109 | 0.090 |
Why?
|
| Vimentin | 2 | 2008 | 66 | 0.090 |
Why?
|
| Anemia | 1 | 2014 | 339 | 0.090 |
Why?
|
| Hematinics | 1 | 2011 | 55 | 0.090 |
Why?
|
| Chagas Disease | 1 | 2014 | 295 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2011 | 136 | 0.080 |
Why?
|
| Electric Stimulation | 4 | 1993 | 326 | 0.080 |
Why?
|
| Brain Death | 3 | 1998 | 61 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2022 | 245 | 0.080 |
Why?
|
| Maze Learning | 2 | 1999 | 128 | 0.080 |
Why?
|
| Hyperglycemia | 4 | 1998 | 225 | 0.070 |
Why?
|
| Neurofibromatosis 1 | 1 | 1989 | 62 | 0.070 |
Why?
|
| Neurofilament Proteins | 1 | 2008 | 28 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1990 | 683 | 0.070 |
Why?
|
| Young Adult | 5 | 2019 | 9056 | 0.070 |
Why?
|
| Hemangioma | 1 | 1989 | 93 | 0.070 |
Why?
|
| Adolescent | 8 | 2022 | 19350 | 0.070 |
Why?
|
| Laser-Doppler Flowmetry | 4 | 2011 | 66 | 0.070 |
Why?
|
| Carcinoma, Small Cell | 1 | 2007 | 51 | 0.070 |
Why?
|
| Mitosporic Fungi | 1 | 2007 | 9 | 0.070 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2007 | 8 | 0.070 |
Why?
|
| Hypotension | 2 | 2019 | 187 | 0.070 |
Why?
|
| Parkinson Disease | 1 | 1993 | 690 | 0.070 |
Why?
|
| Brain Abscess | 1 | 2007 | 50 | 0.060 |
Why?
|
| Genotype | 2 | 2011 | 2564 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 2106 | 0.060 |
Why?
|
| Adenoviridae | 3 | 2000 | 604 | 0.060 |
Why?
|
| Blood Pressure | 7 | 2003 | 1372 | 0.060 |
Why?
|
| Electromyography | 2 | 1996 | 165 | 0.060 |
Why?
|
| Random Allocation | 4 | 2019 | 440 | 0.060 |
Why?
|
| Mice, Knockout | 4 | 2012 | 3744 | 0.060 |
Why?
|
| Time Factors | 9 | 2010 | 6334 | 0.060 |
Why?
|
| Cerebral Infarction | 3 | 1996 | 45 | 0.060 |
Why?
|
| Hypoxia | 3 | 2004 | 250 | 0.060 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2004 | 12 | 0.060 |
Why?
|
| Injections, Spinal | 2 | 2013 | 127 | 0.060 |
Why?
|
| Rats, Inbred Strains | 5 | 1998 | 233 | 0.060 |
Why?
|
| Incidental Findings | 1 | 2005 | 126 | 0.060 |
Why?
|
| Epidural Space | 3 | 1993 | 23 | 0.060 |
Why?
|
| Neurologic Examination | 3 | 2014 | 193 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2011 | 1502 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2011 | 620 | 0.060 |
Why?
|
| Intracranial Hypertension | 3 | 2004 | 125 | 0.060 |
Why?
|
| Neurons | 6 | 2010 | 1932 | 0.060 |
Why?
|
| DNA Copy Number Variations | 2 | 2019 | 949 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2011 | 836 | 0.060 |
Why?
|
| Decision Making | 1 | 2009 | 656 | 0.050 |
Why?
|
| Oxygen Consumption | 4 | 1999 | 305 | 0.050 |
Why?
|
| Neurosurgical Procedures | 2 | 2019 | 302 | 0.050 |
Why?
|
| Cryoglobulins | 1 | 2003 | 2 | 0.050 |
Why?
|
| Spectrum Analysis | 2 | 1993 | 65 | 0.050 |
Why?
|
| Chemokine CCL2 | 1 | 2004 | 122 | 0.050 |
Why?
|
| Scalp | 2 | 1994 | 57 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 187 | 0.050 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 1993 | 128 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2019 | 445 | 0.050 |
Why?
|
| Craniotomy | 2 | 2014 | 109 | 0.050 |
Why?
|
| Microglia | 1 | 2004 | 103 | 0.050 |
Why?
|
| Ischemic Preconditioning | 1 | 2003 | 19 | 0.050 |
Why?
|
| Brain Edema | 2 | 2000 | 68 | 0.050 |
Why?
|
| Treatment Outcome | 9 | 2014 | 12394 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2003 | 61 | 0.050 |
Why?
|
| Aspartic Acid | 2 | 2000 | 73 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 64 | 0.050 |
Why?
|
| Mice, Nude | 3 | 2013 | 708 | 0.050 |
Why?
|
| Vascular Resistance | 1 | 2003 | 189 | 0.050 |
Why?
|
| Motor Neurons | 1 | 2003 | 138 | 0.050 |
Why?
|
| Potassium Channels | 1 | 2003 | 157 | 0.050 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 141 | 0.050 |
Why?
|
| Macrophages | 2 | 2004 | 625 | 0.050 |
Why?
|
| Cell Count | 3 | 2010 | 254 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 144 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2002 | 2893 | 0.050 |
Why?
|
| Glycolysis | 2 | 1999 | 150 | 0.050 |
Why?
|
| Dendritic Cells | 1 | 2004 | 414 | 0.040 |
Why?
|
| Mice | 9 | 2013 | 17632 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 1999 | 435 | 0.040 |
Why?
|
| Taurine | 2 | 1991 | 11 | 0.040 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2003 | 214 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 3 | 2019 | 1329 | 0.040 |
Why?
|
| Prospective Studies | 5 | 2010 | 6159 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 248 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2004 | 2056 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2022 | 389 | 0.040 |
Why?
|
| Astrocytes | 1 | 2003 | 249 | 0.040 |
Why?
|
| Radiography | 3 | 2000 | 822 | 0.040 |
Why?
|
| Microscopy, Polarization | 1 | 1999 | 10 | 0.040 |
Why?
|
| Eye Movements | 1 | 2000 | 70 | 0.040 |
Why?
|
| Phenylephrine | 1 | 1999 | 38 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 1999 | 1020 | 0.040 |
Why?
|
| Hemostatic Techniques | 1 | 1999 | 32 | 0.040 |
Why?
|
| Headache | 1 | 2000 | 107 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2019 | 4 | 0.040 |
Why?
|
| Motor Skills | 1 | 1999 | 83 | 0.040 |
Why?
|
| Oncogene Fusion | 1 | 2019 | 22 | 0.040 |
Why?
|
| Motor Activity | 2 | 1999 | 521 | 0.040 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1999 | 66 | 0.040 |
Why?
|
| Antiviral Agents | 3 | 2000 | 752 | 0.040 |
Why?
|
| Contusions | 1 | 1998 | 18 | 0.040 |
Why?
|
| Glasgow Outcome Scale | 2 | 2014 | 47 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 1999 | 136 | 0.040 |
Why?
|
| Evoked Potentials, Somatosensory | 3 | 1994 | 46 | 0.040 |
Why?
|
| Survival Analysis | 2 | 1999 | 1506 | 0.040 |
Why?
|
| Prognosis | 3 | 2019 | 4642 | 0.040 |
Why?
|
| Mutation | 3 | 2022 | 5842 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 541 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2019 | 135 | 0.040 |
Why?
|
| Telomerase | 1 | 2019 | 160 | 0.040 |
Why?
|
| Suture Techniques | 1 | 1999 | 195 | 0.040 |
Why?
|
| Oximetry | 2 | 1998 | 170 | 0.040 |
Why?
|
| Intralaminar Thalamic Nuclei | 1 | 2017 | 6 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 37 | 0.040 |
Why?
|
| Cell Survival | 3 | 2010 | 813 | 0.040 |
Why?
|
| Energy Metabolism | 5 | 1994 | 766 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 1998 | 60 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2014 | 2913 | 0.040 |
Why?
|
| Sigmodontinae | 1 | 1997 | 44 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1997 | 88 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 1660 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2019 | 618 | 0.030 |
Why?
|
| Infusions, Parenteral | 1 | 1997 | 100 | 0.030 |
Why?
|
| Strychnine | 1 | 1996 | 7 | 0.030 |
Why?
|
| Kynurenic Acid | 1 | 1996 | 8 | 0.030 |
Why?
|
| Dizocilpine Maleate | 1 | 1996 | 18 | 0.030 |
Why?
|
| Nitrogen | 3 | 1993 | 146 | 0.030 |
Why?
|
| Reference Values | 2 | 2014 | 716 | 0.030 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 1996 | 20 | 0.030 |
Why?
|
| Wounds, Gunshot | 1 | 1998 | 139 | 0.030 |
Why?
|
| Hot Temperature | 1 | 1997 | 137 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 1997 | 173 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1997 | 154 | 0.030 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1996 | 48 | 0.030 |
Why?
|
| Resuscitation | 1 | 2019 | 249 | 0.030 |
Why?
|
| DNA, Recombinant | 1 | 1996 | 105 | 0.030 |
Why?
|
| Papio | 1 | 1996 | 60 | 0.030 |
Why?
|
| Skin Neoplasms | 2 | 1994 | 862 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 1 | 1996 | 93 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1996 | 100 | 0.030 |
Why?
|
| Virus Shedding | 1 | 1996 | 80 | 0.030 |
Why?
|
| Mastadenovirus | 1 | 1995 | 2 | 0.030 |
Why?
|
| Osmolar Concentration | 2 | 1993 | 176 | 0.030 |
Why?
|
| Neutralization Tests | 1 | 1996 | 235 | 0.030 |
Why?
|
| Cysteine | 1 | 1996 | 139 | 0.030 |
Why?
|
| Dietary Carbohydrates | 1 | 1996 | 119 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 432 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2000 | 816 | 0.030 |
Why?
|
| S100 Proteins | 2 | 2005 | 46 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 209 | 0.030 |
Why?
|
| Lactates | 4 | 1998 | 94 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 1998 | 490 | 0.030 |
Why?
|
| Organ Specificity | 1 | 1996 | 428 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2011 | 1696 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2016 | 174 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 1998 | 444 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2013 | 3348 | 0.030 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 1994 | 8 | 0.030 |
Why?
|
| DNA, Viral | 1 | 1996 | 480 | 0.030 |
Why?
|
| Growth Disorders | 1 | 1996 | 209 | 0.030 |
Why?
|
| Cauda Equina | 1 | 2014 | 9 | 0.030 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2014 | 4 | 0.030 |
Why?
|
| Persistent Vegetative State | 1 | 2014 | 11 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6600 | 0.030 |
Why?
|
| Laminectomy | 1 | 2014 | 25 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 420 | 0.030 |
Why?
|
| Energy Intake | 2 | 1994 | 494 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 2758 | 0.030 |
Why?
|
| Trypanocidal Agents | 1 | 2014 | 29 | 0.030 |
Why?
|
| Nitroimidazoles | 1 | 2014 | 44 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1995 | 246 | 0.030 |
Why?
|
| Ornithine Decarboxylase | 1 | 1993 | 18 | 0.030 |
Why?
|
| Eflornithine | 1 | 1993 | 15 | 0.030 |
Why?
|
| Cell Death | 1 | 1994 | 240 | 0.030 |
Why?
|
| Carbon Monoxide Poisoning | 1 | 1993 | 13 | 0.030 |
Why?
|
| Regional Blood Flow | 2 | 2010 | 210 | 0.030 |
Why?
|
| Spinal Cord Diseases | 1 | 1993 | 38 | 0.030 |
Why?
|
| Body Temperature | 3 | 1999 | 118 | 0.030 |
Why?
|
| Thromboembolism | 1 | 2014 | 89 | 0.030 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 1 | 2013 | 10 | 0.030 |
Why?
|
| United States | 2 | 2022 | 10918 | 0.030 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2013 | 43 | 0.030 |
Why?
|
| Levodopa | 1 | 1993 | 91 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 5177 | 0.030 |
Why?
|
| Dominance, Cerebral | 1 | 1993 | 56 | 0.030 |
Why?
|
| Central Nervous System | 1 | 1994 | 255 | 0.030 |
Why?
|
| Inclusion Bodies | 1 | 1993 | 48 | 0.030 |
Why?
|
| Atrophy | 1 | 1993 | 230 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1437 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1361 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 1996 | 370 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1711 | 0.030 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 1992 | 20 | 0.020 |
Why?
|
| Hamartoma | 1 | 1993 | 52 | 0.020 |
Why?
|
| Hormones | 1 | 1993 | 186 | 0.020 |
Why?
|
| Diseases in Twins | 1 | 1993 | 94 | 0.020 |
Why?
|
| Meningitis, Bacterial | 1 | 2013 | 95 | 0.020 |
Why?
|
| Catheterization | 1 | 1993 | 235 | 0.020 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2012 | 4 | 0.020 |
Why?
|
| Taenia | 1 | 2012 | 5 | 0.020 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 1 | 2012 | 5 | 0.020 |
Why?
|
| Electrophysiology | 1 | 1993 | 271 | 0.020 |
Why?
|
| Blood Gas Analysis | 3 | 2000 | 86 | 0.020 |
Why?
|
| Brain Concussion | 1 | 1994 | 229 | 0.020 |
Why?
|
| Cerebellar Diseases | 1 | 1992 | 73 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 1993 | 132 | 0.020 |
Why?
|
| Calcinosis | 1 | 1993 | 178 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2011 | 15 | 0.020 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2011 | 15 | 0.020 |
Why?
|
| Rats, Inbred F344 | 3 | 1995 | 106 | 0.020 |
Why?
|
| Trypanosoma cruzi | 1 | 2014 | 236 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 319 | 0.020 |
Why?
|
| Axons | 1 | 1994 | 369 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 506 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 1056 | 0.020 |
Why?
|
| Infusions, Intravenous | 3 | 1999 | 554 | 0.020 |
Why?
|
| Carbohydrate Metabolism | 1 | 1991 | 57 | 0.020 |
Why?
|
| Acute Disease | 1 | 1993 | 1110 | 0.020 |
Why?
|
| Parietal Lobe | 2 | 2005 | 47 | 0.020 |
Why?
|
| Asparagine | 1 | 1990 | 22 | 0.020 |
Why?
|
| Palliative Care | 1 | 2014 | 433 | 0.020 |
Why?
|
| Glutamates | 1 | 1990 | 68 | 0.020 |
Why?
|
| Dichloroacetic Acid | 1 | 1990 | 11 | 0.020 |
Why?
|
| Cholesterol | 1 | 1993 | 541 | 0.020 |
Why?
|
| Electric Stimulation Therapy | 1 | 1991 | 103 | 0.020 |
Why?
|
| Valine | 1 | 1990 | 115 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 1996 | 1153 | 0.020 |
Why?
|
| Acidosis, Lactic | 1 | 1990 | 30 | 0.020 |
Why?
|
| Acetates | 1 | 1990 | 74 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 998 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 515 | 0.020 |
Why?
|
| Blood Glucose | 4 | 1998 | 1131 | 0.020 |
Why?
|
| Chronic Disease | 1 | 1993 | 1195 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 267 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 1990 | 143 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 1068 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2012 | 789 | 0.020 |
Why?
|
| Reaction Time | 1 | 1989 | 175 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 698 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 362 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1995 | 1026 | 0.020 |
Why?
|
| Genes, Dominant | 1 | 1989 | 245 | 0.020 |
Why?
|
| Kinetics | 1 | 1990 | 1332 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2003 | 4404 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 889 | 0.020 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2007 | 14 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2007 | 74 | 0.020 |
Why?
|
| Neck Injuries | 1 | 1987 | 25 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 2821 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2007 | 231 | 0.020 |
Why?
|
| Action Potentials | 1 | 1989 | 502 | 0.020 |
Why?
|
| Pituitary Gland, Posterior | 1 | 2005 | 6 | 0.020 |
Why?
|
| CD56 Antigen | 1 | 2005 | 26 | 0.020 |
Why?
|
| Mucin-1 | 1 | 2005 | 35 | 0.020 |
Why?
|
| Calbindin 2 | 1 | 2005 | 18 | 0.020 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2005 | 25 | 0.020 |
Why?
|
| Autopsy | 1 | 2005 | 113 | 0.020 |
Why?
|
| beta-Galactosidase | 2 | 1995 | 147 | 0.020 |
Why?
|
| Viral Load | 1 | 2007 | 385 | 0.020 |
Why?
|
| Pedigree | 1 | 1989 | 1605 | 0.010 |
Why?
|
| Cerebral Hemorrhage, Traumatic | 1 | 2004 | 3 | 0.010 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2005 | 62 | 0.010 |
Why?
|
| Diet | 1 | 1992 | 1140 | 0.010 |
Why?
|
| Pyruvic Acid | 1 | 2004 | 38 | 0.010 |
Why?
|
| Transduction, Genetic | 2 | 1995 | 289 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2004 | 64 | 0.010 |
Why?
|
| Ketone Bodies | 2 | 1994 | 47 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 1398 | 0.010 |
Why?
|
| Organelles | 1 | 2003 | 21 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2003 | 96 | 0.010 |
Why?
|
| Pia Mater | 1 | 2003 | 10 | 0.010 |
Why?
|
| Phenytoin | 1 | 2003 | 63 | 0.010 |
Why?
|
| Decanoic Acids | 1 | 2003 | 2 | 0.010 |
Why?
|
| Hydroxy Acids | 1 | 2003 | 3 | 0.010 |
Why?
|
| Diazoxide | 1 | 2003 | 8 | 0.010 |
Why?
|
| Arterioles | 1 | 2003 | 28 | 0.010 |
Why?
|
| Body Weight | 2 | 1998 | 989 | 0.010 |
Why?
|
| Capillaries | 1 | 2003 | 66 | 0.010 |
Why?
|
| DNA Primers | 1 | 2004 | 657 | 0.010 |
Why?
|
| Solubility | 1 | 2003 | 139 | 0.010 |
Why?
|
| Potassium Channel Blockers | 1 | 2003 | 84 | 0.010 |
Why?
|
| Lung | 1 | 1990 | 1496 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2003 | 363 | 0.010 |
Why?
|
| Hydrocephalus | 1 | 2004 | 242 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 826 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2003 | 282 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2430 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 257 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2003 | 279 | 0.010 |
Why?
|
| Catecholamines | 2 | 1993 | 59 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 1290 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2007 | 1265 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 676 | 0.010 |
Why?
|
| Hyalin | 1 | 2000 | 6 | 0.010 |
Why?
|
| Anisocoria | 1 | 2000 | 5 | 0.010 |
Why?
|
| Survival Rate | 2 | 1995 | 2063 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2003 | 381 | 0.010 |
Why?
|
| Microelectrodes | 1 | 2000 | 42 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2000 | 59 | 0.010 |
Why?
|
| Body Water | 1 | 1999 | 90 | 0.010 |
Why?
|
| Astrocytoma | 1 | 2000 | 100 | 0.010 |
Why?
|
| Cations | 1 | 1998 | 39 | 0.010 |
Why?
|
| Reflex | 1 | 1998 | 51 | 0.010 |
Why?
|
| Gene Expression | 1 | 2003 | 1561 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1999 | 456 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1998 | 441 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 1998 | 101 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2000 | 899 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1998 | 279 | 0.010 |
Why?
|
| Pyramidal Cells | 1 | 1998 | 171 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 2821 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1997 | 75 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2007 | 2588 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 581 | 0.010 |
Why?
|
| Postural Balance | 1 | 1998 | 125 | 0.010 |
Why?
|
| Seminal Vesicles | 1 | 1996 | 55 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1996 | 189 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1996 | 163 | 0.010 |
Why?
|
| Insulin | 2 | 1992 | 1203 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2000 | 1241 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 2174 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1996 | 308 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2014 | 16342 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2003 | 1497 | 0.010 |
Why?
|
| Pancreas | 1 | 1996 | 221 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 1994 | 15 | 0.010 |
Why?
|
| Eye | 1 | 1996 | 227 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1995 | 376 | 0.010 |
Why?
|
| Hematoma | 1 | 1995 | 93 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1996 | 447 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1996 | 313 | 0.010 |
Why?
|
| Catheterization, Central Venous | 1 | 1995 | 131 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1994 | 107 | 0.010 |
Why?
|
| Karyotyping | 1 | 1994 | 323 | 0.010 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 1 | 1993 | 10 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1996 | 307 | 0.010 |
Why?
|
| Constriction | 1 | 1993 | 50 | 0.010 |
Why?
|
| Genes, p53 | 1 | 1994 | 212 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1995 | 1064 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 369 | 0.010 |
Why?
|
| Child | 1 | 2014 | 24402 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 1993 | 82 | 0.010 |
Why?
|
| Pregnancy | 1 | 2005 | 7202 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1993 | 218 | 0.010 |
Why?
|
| Twins, Monozygotic | 1 | 1993 | 117 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 1994 | 358 | 0.010 |
Why?
|
| Skull | 1 | 1993 | 141 | 0.010 |
Why?
|
| Acetoacetates | 1 | 1991 | 21 | 0.010 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 1991 | 26 | 0.010 |
Why?
|
| Hydroxybutyrates | 1 | 1991 | 44 | 0.010 |
Why?
|
| Fasting | 1 | 1992 | 293 | 0.010 |
Why?
|
| Glycerol | 1 | 1991 | 97 | 0.010 |
Why?
|
| Thymidine | 1 | 1990 | 54 | 0.010 |
Why?
|
| Endothelium | 1 | 1990 | 69 | 0.010 |
Why?
|
| Bronchi | 1 | 1990 | 99 | 0.010 |
Why?
|
| Critical Care | 1 | 1995 | 657 | 0.010 |
Why?
|
| Pulmonary Alveoli | 1 | 1990 | 135 | 0.010 |
Why?
|
| Kidney | 1 | 1996 | 1365 | 0.000 |
Why?
|
| Cell Division | 1 | 1990 | 782 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1988 | 144 | 0.000 |
Why?
|
| Cardiac Output | 1 | 1988 | 171 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 1990 | 909 | 0.000 |
Why?
|
| Proteins | 1 | 1991 | 1036 | 0.000 |
Why?
|
| DNA | 1 | 1990 | 1608 | 0.000 |
Why?
|
| Electroencephalography | 1 | 1987 | 865 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1993 | 8225 | 0.000 |
Why?
|